Evidence map›Paper›PMID 36511902›Full record

ArticleMolecular cancer research : MCR2023

The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.

Chaoran Ma, Yinglu Zhou, Giuseppe Nicolò Fanelli, Konrad H Stopsack, Michelangelo Fiorentino, Giorgia Zadra, Lorelei A Mucci, Massimo Loda, Svitlana Tyekucheva, Kathryn L Penney

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Chaoran Ma *Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3683-3218
Yinglu Zhou *Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-6276-635X
Giuseppe Nicolò FanelliUniversity of Padua, Padua, Italy.ORCID 0000-0001-7069-7980
Konrad H StopsackHarvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-0722-1311
Michelangelo FiorentinoUniversity of Bologna, School of Medicine, Bologna, Italy.ORCID 0000-0002-1749-150X
Giorgia ZadraInstitute of Molecular Genetics, National Research Council, Pavia, Italy.ORCID 0000-0002-8123-1358
Lorelei A MucciHarvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0002-2551-4927
Massimo LodaWeill Cornell Medicine, New York, New York.ORCID 0000-0001-9674-8379
Svitlana Tyekucheva *Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3119-6507
Kathryn L Penney *Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-2815-3450
Harvard University · USBrigham and Women's Hospital · USCornell University · USDana-Farber Cancer Institute · USNational Research Council · ITUniversity of Bologna · ITUniversity of Padua · IT

Funding

Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancerR37CA227190 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M, TYEKUCHEVA, SVITLANA · 2018 to 2024
$3.6M
NCI NIH HHS R37 CA227190NCI NIH HHS U01 CA167552
6 · The paper itself

Abstract

Prostate cancer has a heterogeneous prognosis. Most previous studies have focused on the identification of prognostic biomarkers in the prostate cancer tumor. However, it is increasingly recognized that the tumor microenvironment contributes to prostate cancer aggressiveness and progression. We therefore examined whole transcriptome expression of the prostate stroma and associations with aggressive and lethal prostate cancer. We performed RNA sequencing (Illumina TruSeq Exome Capture) of 272 tumor-adjacent and 120 benign-adjacent macrodissected prostate stromal samples from 293 men with prostate cancer from the Health Professionals Follow-up Study and Physicians' Health Study. We performed differential expression analysis comparing gene expression and pathways by Gleason score and lethal outcome. We also tested a previously developed stromal gene signature of Gleason score in these datasets. Comparing high- with low-Gleason score cancers, 26 genes (P < 0.001) and 12 pathways (FDR < 0.20) were significantly differentially expressed in tumor-adjacent stroma, including pathways related to stroma composition remodeling and DNA repair, with 73 genes and 65 pathways significant in benign-adjacent stroma. Comparing lethal with nonlethal prostate cancer, 11 genes were differentially expressed in tumor-adjacent and 15 genes in benign-adjacent stroma, and pathways involved in inflammatory response were differentially enriched in both tumor and benign-adjacent stroma. In addition, our previously identified Gleason stromal gene signature was validated to be associated with Gleason score in these data. Implications: Our study uncovers stroma-specific genes and pathways that are differentially enriched with high Gleason score and lethal prostate cancer, demonstrating that the molecular investigation of the tumor microenvironment can provide additional information about prostate cancer prognosis.

Indexed as

ProstateProstatic NeoplasmsBiomarkers, TumorFollow-Up StudiesGene Expression Regulation, NeoplasticHumansMaleNeoplasm GradingTranscriptomeTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID36511902
PMCPMC9991973
OpenAlexW4311281368

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.